|

Ubamatamab Clinical Trials

4 actively recruiting trials across 2 locations

▼ -1 trial since August 2026

Also known as: REGN4018

Pipeline

Phase 2: 2Phase 1/2: 2

Top Sponsors

  • Regeneron Pharmaceuticals4

Indications

  • Cancer4
  • Fallopian Tube Cancer2
  • Primary Peritoneal Cancer2
  • Endometrial Cancer2
  • Ovarian Cancer2

Birmingham, Alabama3 trials

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

University of Alabama at Birmingham

Phase 2
Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer

The University of Alabama at Birmingham

Phase 2
Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

University of Alabama_6th Ave

Phase 1/2

Duarte, California1 trial

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

City of Hope Comprehensive Cancer Center

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.